Table 1.
Basic characteristics of RCTs.
| Author | Year | Number of cases T/C (eyes) | Age | Duration of diabetes | Interventions (T/C) | The course of treatment (mo) | Outcome |
|---|---|---|---|---|---|---|---|
| Sun GL[15] | 2017 | 15/15 | 58.27 ± 6.85 57.69 ± 6.39 |
NA | SML + ranibizumab/ Ranibizumab |
12–17 13–20 |
①②④⑤ |
| Li WQ[16] | 2019 | 36/32 | 57.2 ± 10.1 60.6 ± 12.3 |
NA | SML + conbercept/ Conbercept |
12 | ① ②③ ④ |
| Huang KQ[13] | 2022 | 26/26 | 62.31 ± 5.48 63.77 ± 5.37 |
62.81 ± 20.01/ 64.04 ± 20.44 (mo) |
SML + ranibizumab/ Ranibizumab |
9 | ① ② ④ |
| Mao YJ[18] | 2022 | 34/34 | 50.35 ± 10.14 51.47 ± 11.23 |
6.74 ± 2.03/ 6.80 ± 2.11 (yr) |
SML + aflibercept/ Aflibercept |
12 | ① ② ④⑤⑧ |
| Zhang Q[14] | 2021 | 35/35 | 56.0 ± 7.7/ 53.3 ± 9.1 |
13.5 ± 4.2/ 12.9 ± 4.1 (yr) |
SML + aflibercept/ Aflibercept |
12 | ① ② ④ |
| Chen SN[25] | 2020 | 30/28 | 56.17 ± 5.44/ 58.68 ± 5.92 |
NA | SML + ranibizumab/ Ranibizumab |
12 | ① ②③ ④⑦ |
| Yan LJ[21] | 2019 | 40/38 | 59.7 ± 4.5/ 56.9 ± 4.4 |
12.7 ± 3.3/ 13.4 ± 3.7 (yr) |
SML + ranibizumab/ Ranibizumab |
NA | ① ② ④ |
| Wu Q[20] | 2021 | 36/36 | 56.8 ± 10.2 56.3 ± 9.5 |
NA | SML + ranibizumab/ Ranibizumab |
9 | ① ②③ ④⑥ |
| Liu HX[26] | 2021 | 44/44 | 69.57 ± 5.31 68.16 ± 3.28 |
6.72 ± 1.31/ 6.72 ± 1.31 (yr) |
SML + ranibizumab/ SML |
1 | ① ②⑤⑧ |
| Akhlaghi[10] | 2019 | 42/42 | 60.86 ± 8.57 60.86 ± 8.57 |
NA | SML + bevacizumab/ Bevacizumab |
4 | ① ② |
| Tatsumi[9] | 2020 | 22/21 | NA | NA | SML + aflibercept/ Aflibercept |
24 | ① ② ④⑤ |
| Abouhussein[17] | 2020 | 20/20 | 60.4 ± 4.2/ 59.5 ± 4.3 |
NA | SML + aflibercept/ Aflibercept |
12 | ① ② ④⑤ |
| Khattab[11] | 2019 | 27/27 | 59.4 ± 4.3/ 55.7 ± 3.4 |
17.8 ± 3.4/ 17.4 ± 4.2 (yr) |
SML + aflibercept/ Aflibercept |
18 | ① ② ⑤ |
| Kanar[19] | 2019 | 28/28 | 63.43 ± 10.14/ 62.64 ± 9.03 |
18.76 ± 2.08/ 18.28 ± 2.24 (yr) |
SML + aflibercept/ Aflibercept |
12 | ① ②③ ④⑥ |
| Koushan[22] | 2022 | 15/15 | 59.8 ± 9.47/ 58.8 ± 9.28 |
NA | SML + aflibercept/ Aflibercept + sham SML |
12 | ① ②③ ④ |
①BCVA; ②CMT; ③TMV; ④The number of anti-VEGF drugs; ⑤Complications.
RCTs = randomized controlled trials, SML = subthreshold micropulse laser.